Product Disclosures

Reflecting standard oncology practice, which often requires the off-label or investigational use of some products, this educational activity includes information about many drugs. All faculty participating in continuing education activities are expected to disclose the approved or investigational status (related to the subject matter of this activity—colorectal cancer) of all products and devices under discussion. This information, as of the time of printing, is summarized briefly in the table below. In addition, primary references and full prescribing information should be consulted for complete information. Clinicians have the professional responsibility to ensure that drugs are prescribed and used appropriately, based on their own clinical judgment and accepted standards of care.

Generic Name Brand Name FDA Approved for the Treatment of Colorectal Cancer FDA Approved for Other Indications Investigational for the Treatment of Colorectal Cancer
Bevacizumab Avastin X    
Capecitabine Xeloda X X  
Celecoxib Celebrex

 

 X X
Cetuximab Erbitux X    
Cisplatin Platinol

 

 X  
Doxorubicin Adriamycin   X  
Erlotinib Tarceva     X
Fluorouracil
(5-FU)		 Adrucil X X  
Gefitinib Iressa   X X
Irinotecan Camptosar X    
Leucovorin (folinic acid) Wellcovorin, various X X  
Levamisole Ergamisol X    
Oxaliplatin Eloxatin X    
Paclitaxel Taxol, Onxol   X  

Adapted from Drug Facts and Comparisons. St Louis, Mo: Facts & Comparisons; 2004.